Beijert, Irene J. and Hentschel, Anouk E. and Brundl, Johannes and Comperat, Eva M. and Plass, Karin and Rodriguez, Oscar and Henriquez, Jose D. Subiela and Henraquez, Virginia and de la Pena, Enrique and Alemany, Isabel and Turturica, Diana and Pisano, Francesca and Soria, Francesco and Capoun, Otakar and Bauerova, Lenka and Pesl, Michael and Bruins, H. Maxim and Runneboom, Willemien and Herdegen, Sonja and Breyer, Johannes and Brisuda, Antonin and Calatrava, Ana and Rubio-Briones, Jose and Seles, Maximilian and Mannweiler, Sebastian and Bosschieter, Judith and Kusuma, Venkata R. M. and Ashabere, David and Huebner, Nicolai and Cotte, Juliette and Mertens, Laura S. and Claps, Francesco and Masson-Lecomte, Alexandra and Liedberg, Fredrik and Cohen, Daniel and Lunelli, Luca and Cussenot, Olivier and El Sheikh, Soha and Volanis, Dimitrios and Cote, Jean-Francois and Roupret, Morgan and Haitel, Andrea and Shariat, Shahrokh F. and Mostafid, A. Hugh and Nieuwenhuijzen, Jakko A. and Zigeuner, Richard and Dominguez-Escrig, Jose L. and Hacek, Jaromir and Zlotta, Alexandre R. and Zigeuner, Maximilian and Evert, Matthias and Hulsbergen-van de Kaa, Christina A. and van der Heijden, Antoine G. and Kiemeney, Lambertus A. L. M. and Soukup, Viktor and Molinaro, Luca and Gontero, Paolo and Llorente, Carlos and Algaba, Ferran and Palou, Joan and N'Dow, James and Ribal, Maria J. and van der Kwast, Theo H. and Babjuk, Marko and Sylvester, Richard J. and van Rhijn, Bas W. G. (2023) Prognosis of Primary Papillary Ta Grade 3 Bladder Cancer in the Non-muscle-invasive Spectrum. EUROPEAN UROLOGY ONCOLOGY, 6 (2). pp. 214-221. ISSN , 2588-9311
Full text not available from this repository. (Request a copy)Abstract
Background: Ta grade 3 (G3) non-muscle-invasive bladder cancer (NMIBC) is a rela-tively rare diagnosis with an ambiguous character owing to the presence of an aggres-sive G3 component together with the lower malignant potential of the Ta component. The European Association of Urology (EAU) NMIBC guidelines recently changed the risk stratification for Ta G3 from high risk to intermediate, high, or very high risk. However, prognostic studies on Ta G3 carcinomas are limited and inconclusive.Objective: To evaluate the prognostic value of categorizing Ta G3 compared to Ta G2 and T1 G3 carcinomas.Design, setting, and participants: Individual patient data for 5170 primary Ta-T1 blad-der tumors from 17 hospitals were analyzed. Transurethral resection of the tumor was performed between 1990 and 2018.Outcome measurements and statistical analysis: Time to recurrence and time to progres-sion were analyzed using cumulative incidence functions, log-rank tests, and multivari-able Cox-regression models with interaction terms stratified by institution.Results and limitations: Ta G3 represented 7.5% (387/5170) of Ta-T1 carcinomas of which 42% were classified as intermediate risk. Time to recurrence did not differ between Ta G3 and Ta G2 (p = 0.9) or T1 G3 (p = 0.4). Progression at 5 yr occurred for 3.6% (95% confidence interval [CI] 2.7-4.8%) of Ta G2, 13% (95% CI 9.3-17%) of Ta G3, and 20% (95% CI 17-23%) of T1 G3 carcinomas. Time to progression for Ta G3 was shorter than for Ta G2 (p < 0.001) and longer than for T1 G3 (p = 0.002). Patients with Ta G3 NMIBC with concomitant carcinoma in situ (CIS) had worse prognosis and a similar time to progression as for patients with T1 G3 NMIBC with CIS (p = 0.5). Multivariable anal-yses for recurrence and progression showed similar results. Conclusions: The prognosis of Ta G3 tumors in terms of progression appears to be in between that of Ta G2 and T1 G3. However, patients with Ta G3 NMIBC with concomi-tant CIS have worse prognosis that is comparable to that of T1 G3 with CIS. Our results support the recent EAU NMIBC guideline changes for more refined risk stratification of Ta G3 tumors because many of these patients have better prognosis than previously thought.Patient summary: We used data from 17 centers in Europe and Canada to assess the prognosis for patients with stage Ta grade 3 (G3) non-muscle-invasive bladder cancer (NMIBC). Time to cancer progression for Ta G3 cancer differed from both Ta G2 and T1 G3 tumors. Our results support the recent change in the European Association of Urology guidelines for more refined risk stratification of Ta G3 NMIBC because many patients with this tumor have better prognosis than previously thought.(c) 2023 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology. This is an open access article under the CC BY license (http://creativecommons. org/licenses/by/4.0/).
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | PROGRESSION; TUMORS; RECURRENCE; STAGE; RISK; PATHOLOGY; IMPACT; Bladder; Cancer; Carcinomas; Grade; G3; Non-muscle-invasive; Stage Ta; Urothelial; World Health Organization |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Pathologie Medicine > Lehrstuhl für Urologie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 30 Jan 2024 10:28 |
| Last Modified: | 30 Jan 2024 10:28 |
| URI: | https://pred.uni-regensburg.de/id/eprint/60832 |
Actions (login required)
 |
View Item |
